AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36026657 — intervention group
Group type: COMPARATOR
Intervention: Isometric Handgrip (IH)
Number of subjects: 70
Study 36026657 — intervention group
Group type: COMPARATOR
Intervention: Control (CO) - seated resting
Number of subjects: 70
Study 33899450 — intervention group
Group type: EXPERIMENTAL
Intervention: ALMAG + magnetic therapy device
Number of subjects: 70
Study 33899450 — intervention group
Group type: COMPARATOR
Intervention: Placebo devices
Number of subjects: 70
Study 36088457 — intervention group
Group type: EXPERIMENTAL
Intervention: PROGROUP (a novel group-based behavioural intervention)
Number of subjects: 0
Study 36088457 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 32484754 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) treatments (arm 1)
Number of subjects: 99
Study 32484754 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC plus stereotactic ablative radiotherapy (SABR) (arm 2)
Number of subjects: 99
Study 34479861 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTp with sulfadoxine‐pyrimethamine (SP) and azithromycin (AZI)
Number of subjects: 1320
Study 34479861 — intervention group
Group type: COMPARATOR
Intervention: Control (twice with SP)
Number of subjects: 1320
Study 34996111 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive VR (IVR) using Oculus Go Standalone headset with games (Temple Run or Roller Coaster)
Number of subjects: 200
Study 34996111 — intervention group
Group type: COMPARATOR
Intervention: Non-immersive VR (NIVR) watching cartoon movies
Number of subjects: 200
Study 36205268 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS)
Number of subjects: 0
Study 36205268 — intervention group
Group type: COMPARATOR
Intervention: Standard diagnostic strategies (Control)
Number of subjects: 0
Study 34127127 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine
Number of subjects: 295
Study 34127127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study 32591246 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC + prostate RT
Number of subjects: 660
Study 32591246 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 660
Study 35780104 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physio-hemsball training for 8 weeks
Number of subjects: 30
Study 35780104 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 34611000 — intervention group
Group type: EXPERIMENTAL
Intervention: iPACK block
Number of subjects: 80
Study 34611000 — intervention group
Group type: COMPARATOR
Intervention: Periarticular local infiltration analgesia (LIA)
Number of subjects: 80
Study 32579813 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea with dose escalation (approximately 30 mg per kilogram per day)
Number of subjects: 187
Study 32579813 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea at a fixed dose (approximately 20 mg per kilogram of body weight per day)
Number of subjects: 187
Study 32579813 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose escalation group
Number of subjects: 187
Study 615918278 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2.0 mg every 8 weeks after 3 initial monthly doses (2q8)
Number of subjects: 799
Study 35114057 — intervention group
Group type: EXPERIMENTAL
Intervention: mesorectal long course chemoradiation
Number of subjects: 500
Study 35114057 — intervention group
Group type: EXPERIMENTAL
Intervention: mesorectal short course radiotherapy with selective transanal microsurgery
Number of subjects: 500
Study 35114057 — intervention group
Group type: COMPARATOR
Intervention: Total mesorectal excision (TME)
Number of subjects: 500
Study 35114057 — intervention group
Group type: EXPERIMENTAL
Intervention: acute treatment-related toxicity
Number of subjects: 500
Study 35114057 — intervention group
Group type: EXPERIMENTAL
Intervention: non-operative management
Number of subjects: 500
Study 35114057 — intervention group
Group type: EXPERIMENTAL
Intervention: non-regrowth pelvic tumour control at 36 months
Number of subjects: 500
Study 35114057 — intervention group
Group type: EXPERIMENTAL
Intervention: non-regrowth disease free survival at 36 months
Number of subjects: 500
Study 35114057 — intervention group
Group type: EXPERIMENTAL
Intervention: overall survival at 60 months
Number of subjects: 500
Study 35114057 — intervention group
Group type: EXPERIMENTAL
Intervention: patient reported toxicity
Number of subjects: 500
Study 35114057 — intervention group
Group type: EXPERIMENTAL
Intervention: health related QOL
Number of subjects: 500
Study 33285371 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES) for 7 consecutive days
Number of subjects: 47
Study 33285371 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES)
Number of subjects: 47
Study 33914945 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial Direct Current Stimulation (tDCS) to the ventrolateral prefrontal cortex
Number of subjects: 40
Study 33914945 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 40
Study 32744358 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin + PEX168 100 μg
Number of subjects: 44
Study 32744358 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin + PEX168 200 μg
Number of subjects: 44
Study 32744358 — intervention group
Group type: COMPARATOR
Intervention: metformin + placebo
Number of subjects: 44
Study 35543263 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Analgesia (TEA)
Number of subjects: 131
Study 35543263 — intervention group
Group type: COMPARATOR
Intervention: Rectus Sheath Catheter Analgesia (RSCA)
Number of subjects: 131
Study 32060740 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week heavy-load strength-training program
Number of subjects: 0
Study 32060740 — intervention group
Group type: EXPERIMENTAL
Intervention: Early training sessions
Number of subjects: 0
Study 32060740 — intervention group
Group type: EXPERIMENTAL
Intervention: Later training sessions
Number of subjects: 0
Study 32060740 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week strength-training program
Number of subjects: 0
Study 32060740 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study 35272403 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency acupuncture (5 times weekly for weeks 1-4, 3 times weekly for weeks 5-8)
Number of subjects: 120
Study 35272403 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency acupuncture (3 times weekly for weeks 1-4, 2 times weekly for weeks 5-8)
Number of subjects: 120
Study 35272403 — intervention group
Group type: COMPARATOR
Intervention: High nicotine metabolite rate (NMR) patients
Number of subjects: 120
Study 35272403 — intervention group
Group type: COMPARATOR
Intervention: Low nicotine metabolite rate (NMR) patients
Number of subjects: 120
Study 34077434 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute apple cider vinegar (0.5% acetic acid)
Number of subjects: 22
Study 34077434 — intervention group
Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 22
Study 34077434 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 22
Study 35668567 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine plus ulinastatin
Number of subjects: 100
Study 35668567 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (control group)
Number of subjects: 100
Study 33860924 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat plus guideline-directed medical therapy (GDMT)
Number of subjects: 20510
Study 33860924 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) plus placebo
Number of subjects: 20510
Study 33091174 — intervention group
Group type: EXPERIMENTAL
Intervention: High fermentable fiber intake (13 g)
Number of subjects: 18
Study 33091174 — intervention group
Group type: COMPARATOR
Intervention: Low fermentable fiber intake (≤ 2 g)
Number of subjects: 18
Study 33091174 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical coating dissolution profiles
Number of subjects: 18
Study 36691173 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of 11.4 mg betamethasone
Number of subjects: 88
Study 36691173 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 88
Study 35995785 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab 7000 mg
Number of subjects: 317
Study 35995785 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab 700 mg
Number of subjects: 317
Study 35995785 — intervention group
Group type: COMPARATOR
Intervention: Blinded placebo
Number of subjects: 317
Study 35995785 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab
Number of subjects: 317
Study 33992566 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about prognosis generated from electronic health record and presented to providers.
Number of subjects: 3124
Study 32826015 — intervention group
Group type: EXPERIMENTAL
Intervention: IASTM
Number of subjects: 16
Study 32826015 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration Massage
Number of subjects: 16
Study 32826015 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Hand Massage
Number of subjects: 16
Study 32228099 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene
Number of subjects: 213
Study 32228099 — intervention group
Group type: COMPARATOR
Intervention: Polyglactin 910
Number of subjects: 213
Study 34627611 — intervention group
Group type: EXPERIMENTAL
Intervention: DMUC4064A (5.2 mg/kg RP2D)
Number of subjects: 65
Study 34627611 — intervention group
Group type: EXPERIMENTAL
Intervention: DMUC4064A (≥3.2 mg/kg)
Number of subjects: 65
Study 34627611 — intervention group
Group type: EXPERIMENTAL
Intervention: DMUC4064A
Number of subjects: 65
Study 32174632 — intervention group
Group type: EXPERIMENTAL
Intervention: Bach flower therapy (BFT)
Number of subjects: 120
Study 32174632 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (MT)
Number of subjects: 120
Study 32174632 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 35508656 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG319
Number of subjects: 21
Study 35508656 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent dosing of PI3Kδi
Number of subjects: 21
Study 33120207 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (HF) intervention
Number of subjects: 274
Study 33120207 — intervention group
Group type: COMPARATOR
Intervention: Discrimination and stigma trajectories
Number of subjects: 274
Study 33120207 — intervention group
Group type: COMPARATOR
Intervention: Housing stability
Number of subjects: 274
Study 33120207 — intervention group
Group type: COMPARATOR
Intervention: Recovery
Number of subjects: 274
Study 33120207 — intervention group
Group type: COMPARATOR
Intervention: Quality of life
Number of subjects: 274
Study 33120207 — intervention group
Group type: COMPARATOR
Intervention: Community functioning
Number of subjects: 274
Study 34558835 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin (50 mg/day for 72 weeks)
Number of subjects: 51
Study 34558835 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SGLT2is, pioglitazone, GLP-1 analogs, or insulin)
Number of subjects: 51
Study 33610212 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab 320 mg every 4 weeks
Number of subjects: 0
Study 33610212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36241463 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg plus ezetimibe 10 mg
Number of subjects: 0
Study 36241463 — intervention group
Group type: COMPARATOR
Intervention: Pitavastatin 2 mg
Number of subjects: 0
Study 36241463 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg plus ezetimibe 10 mg
Number of subjects: 0
Study 36241463 — intervention group
Group type: COMPARATOR
Intervention: Pitavastatin 4 mg
Number of subjects: 0
Study 33027558 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depressive disorder (MDD)
Number of subjects: 44
Study 33027558 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive status (ever depressed for a whole week)
Number of subjects: 44
Study 32408795 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led intervention
Number of subjects: 12
Study 32408795 — intervention group
Group type: COMPARATOR
Intervention: Staff-led activity group (usual care)
Number of subjects: 12
Study 33057705 — intervention group
Group type: COMPARATOR
Intervention: no-PADN
Number of subjects: 45
Study 33057705 — intervention group
Group type: EXPERIMENTAL
Intervention: instant-PADN
Number of subjects: 45
Study 33057705 — intervention group
Group type: EXPERIMENTAL
Intervention: 1M-PADN
Number of subjects: 45
Study 33057705 — intervention group
Group type: EXPERIMENTAL
Intervention: 2M-PADN
Number of subjects: 45
Study 33057705 — intervention group
Group type: EXPERIMENTAL
Intervention: 3M-PADN
Number of subjects: 45
Study 35392963 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid (1 g orally twice per day for 180 days)
Number of subjects: 120
Study 35392963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 34115990 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose Optimization for Stone Evaluation intervention (customized CME modules, personalized consultation, and protocol recommendations for RDCT)
Number of subjects: 314
Study 34115990 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervened-on group
Number of subjects: 314
Study 34115990 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 314
Study 33415869 — intervention group
Group type: EXPERIMENTAL
Intervention: Huayu Tongluo moxibustion applied at Baihui (GV 20), Dazhui (GV 14), Shenting (GV 24), once every 2 days for 4 weeks, total of 3 courses
Number of subjects: 47
Study 33415869 — intervention group
Group type: COMPARATOR
Intervention: Conventional hypoglycemic intervention
Number of subjects: 47
Study 33860116 — intervention group
Group type: EXPERIMENTAL
Intervention: Resmetirom (80 or 100 mg orally per day)
Number of subjects: 31
Study 32428586 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 840
Study 32428586 — intervention group
Group type: COMPARATOR
Intervention: Online Program (OP)
Number of subjects: 840
Study 32428586 — intervention group
Group type: COMPARATOR
Intervention: Combined Intervention (CI)
Number of subjects: 840
Study 36217872 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran sodium 300 mg/284 mg (free acid) administered at days 1, 90, 270 and 450
Number of subjects: 298
Study 36217872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 33331857 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated palliative and oncology care (IPC)
Number of subjects: 160
Study 32703194 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine drops (5 mg, four daily doses for 1 week)
Number of subjects: 36
Study 32703194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 35384021 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rituximab (500 mg, 2 weeks apart)
Number of subjects: 23
Study 35384021 — intervention group
Group type: COMPARATOR
Intervention: Rheumatoid arthritis protocol (1000 mg given as two doses, 2 weeks apart)
Number of subjects: 23
Study 35384021 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received short-term oral corticosteroids
Number of subjects: 23
Study 33491116 — intervention group
Group type: EXPERIMENTAL
Intervention: Process-based incentive arm
Number of subjects: 240
Study 33491116 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome-based incentive arm
Number of subjects: 240
Study 33491116 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined incentive arms
Number of subjects: 240
Study 33491116 — intervention group
Group type: EXPERIMENTAL
Intervention: Process-based incentives
Number of subjects: 240
Study 33491116 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus (UC +)
Number of subjects: 240
Study 32268815 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide, bortezomib, and low-dose dexamethasone (PVd)
Number of subjects: 0
Study 32268815 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib and low-dose dexamethasone (Vd)
Number of subjects: 0
Study 34459271 — intervention group
Group type: EXPERIMENTAL
Intervention: Education (brief psychoeducation and treatment resources)
Number of subjects: 267
Study 34459271 — intervention group
Group type: EXPERIMENTAL
Intervention: Education+Motivation (Education plus treatment seeking-focused motivational content)
Number of subjects: 267
Study 34662275 — intervention group
Group type: EXPERIMENTAL
Intervention: Anecdote alone
Number of subjects: 222
Study 34662275 — intervention group
Group type: EXPERIMENTAL
Intervention: Anecdote combined with clinical trial evidence
Number of subjects: 222
Study 34662275 — intervention group
Group type: COMPARATOR
Intervention: Clinical trial evidence alone
Number of subjects: 222
Study 32078787 — intervention group
Group type: EXPERIMENTAL
Intervention: AkP05 nutraceutical combination
Number of subjects: 69
Study 32078787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 32078787 — intervention group
Group type: COMPARATOR
Intervention: Diuretic
Number of subjects: 69
Study 35314453 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified speed CPET
Number of subjects: 22
Study 35314453 — intervention group
Group type: COMPARATOR
Intervention: Fixed speed CPET
Number of subjects: 22
Study 33249593 — intervention group
Group type: EXPERIMENTAL
Intervention: high-dose rhIGF‐1/rhIGFBP‐3 (60 mg/day)
Number of subjects: 56
Study 33249593 — intervention group
Group type: EXPERIMENTAL
Intervention: low-dose rhIGF‐1/rhIGFBP‐3 (30 mg/day)
Number of subjects: 56
Study 35665824 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D visualization
Number of subjects: 47
Study 35665824 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D visualization
Number of subjects: 47
Study 35665824 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study 33392696 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-prefrontal transcranial direct current stimulation (tDCS) applied to both the right inferior frontal gyrus (IFG) and dorsolateral prefrontal cortex (DLPFC) with 9 cm2 electrodes, using anodal or cathodal stimulation over the IFG and opposite polarity over the DLPFC.
Number of subjects: 45
Study 33392696 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS stimulation, which involved short stimulation at the start, middle, and end of the supposed 20-minute stimulation period.
Number of subjects: 45
Study 32740188 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-implemented goal-directed sedation strategy (cardiac-RESTORE)
Number of subjects: 1243
Study 35462371 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC) 10 g once daily during the maintenance phase
Number of subjects: 0
Study 35462371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33888245 — intervention group
Group type: EXPERIMENTAL
Intervention: PARADIGM-HF
Number of subjects: 1038
Study 33888245 — intervention group
Group type: EXPERIMENTAL
Intervention: PARAGON-HF
Number of subjects: 1038
Study 36043350 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 10 mg once daily for 12 weeks
Number of subjects: 110
Study 36043350 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 110
Study 35616507 — intervention group
Group type: EXPERIMENTAL
Intervention: DFT015 intraocular lens (AcrySof IQ Vivity Extended Vision)
Number of subjects: 218
Study 35616507 — intervention group
Group type: COMPARATOR
Intervention: SN60WF aspheric monofocal control IOL (AcrySof IQ model SN60WF)
Number of subjects: 218
Study 33020099 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted case finding
Number of subjects: 1621
Study 33020099 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1621
Study 33020099 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients added to a COPD register
Number of subjects: 1621
Study 35778882 — intervention group
Group type: EXPERIMENTAL
Intervention: Essence containing royal jelly extract
Number of subjects: 35
Study 35778882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 32632763 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face treatment (10 sessions, 60 minutes each)
Number of subjects: 281
Study 32632763 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity treatment (information delivered in printed or electronic format, supported by up to four telephone sessions)
Number of subjects: 281
Study 32632763 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face treatment
Number of subjects: 281
Study 32632763 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity delivery
Number of subjects: 281
Study 35450913 — intervention group
Group type: COMPARATOR
Intervention: Complex continuum of care intervention delivered by community health workers, including health literacy material, multimicronutrient supplement, health services, feedback, and behaviour change support sessions.
Number of subjects: 6800
Study 32962539 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Task (CT) - Stroop task
Number of subjects: 9
Study 32962539 — intervention group
Group type: COMPARATOR
Intervention: Control Condition (CON) - viewing a documentary exhibition
Number of subjects: 9
Study 35062988 — intervention group
Group type: EXPERIMENTAL
Intervention: Naoxintong capsules (NXT)
Number of subjects: 128
Study 35062988 — intervention group
Group type: EXPERIMENTAL
Intervention: Buyang Huanwu granules (BYHW)
Number of subjects: 128
Study 35062988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 32007169 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological cardioversion followed by electrical cardioversion (drug-shock)
Number of subjects: 396
Study 32007169 — intervention group
Group type: COMPARATOR
Intervention: Electrical cardioversion alone (shock-only)
Number of subjects: 396
Study 32007169 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug infusion only (part of drug-shock group)
Number of subjects: 396
Study 32007169 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral pad positions
Number of subjects: 396
Study 32007169 — intervention group
Group type: COMPARATOR
Intervention: Anteroposterior pad positions
Number of subjects: 396
Study 35306247 — intervention group
Group type: EXPERIMENTAL
Intervention: 5inD mobile application
Number of subjects: 57